Cargando…

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449632/ https://www.ncbi.nlm.nih.gov/pubmed/34548805 http://dx.doi.org/10.2147/JIR.S338699

Ejemplares similares

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
por: Luo, Min, et al.
Publicado: (2021)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2022)

HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
por: Xu, Yituo, et al.
Publicado: (2021)

Corrigendum to “Expression of HIF-2α and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance”
por: Zhang, Lixia, et al.
Publicado: (2017)

Corrigendum to “Clinical Significance of the Decreased Expression of hsa_circ_001242 in Oral Squamous Cell Carcinoma”
por: Sun, Shuai, et al.
Publicado: (2019)

Corrigendum to “Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma”
por: Fatima, Naz, et al.
Publicado: (2017)

Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum]
Publicado: (2020)

[Corrigendum] MicroRNA‑92a contributes to tumor growth of human hepatocellular carcinoma by targeting FBXW7
por: Yang, Wei, et al.
Publicado: (2023)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum]
Publicado: (2020)

Corrigendum to “The Oncogenic Role of ARG1 in Progression and Metastasis of Hepatocellular Carcinoma”
por: You, Jia, et al.
Publicado: (2019)

Corrigendum to: Downregulation of SETD5 Suppresses the Tumorigenicity of Hepatocellular Carcinoma Cells
por: Park, Mijin, et al.
Publicado: (2022)

Corrigendum to “Cell Cycle Genes Are Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma”
por: Liping, Xu, et al.
Publicado: (2020)

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2023)

Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum]
Publicado: (2021)

Corrigendum to “Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach”
Publicado: (2021)

Corrigendum to “Expression of HE4 in Endometrial Cancer and Its Clinical Significance”
por: Li, Xiao, et al.
Publicado: (2018)

HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer
por: Yang, Zeng, et al.
Publicado: (2022)

Molecular Epidemiology And Clinical Significance Of Corynebacterium Striatum Isolated From Clinical Specimens [Corrigendum]
Publicado: (2019)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Corrigendum to “The Prognostic Significance of Tumor Deposit Count for Colorectal Cancer Patients after Radical Surgery”
por: Zheng, Kuo, et al.
Publicado: (2020)

Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection [Corrigendum]
Publicado: (2021)

Corrigendum to “Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells”
por: Huang, Suning, et al.
Publicado: (2020)

Downregulation of CENPK Suppresses Hepatocellular Carcinoma Malignant Progression through Regulating YAP1 [Corrigendum]
Publicado: (2022)

Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis [Corrigendum]
Publicado: (2022)

KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
por: Li, Yang, et al.
Publicado: (2022)

Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis
por: Wang, Ben, et al.
Publicado: (2019)

Corrigendum to “System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma”
por: Xu, Jun Hui, et al.
Publicado: (2022)

miR-500a-3p is a Potential Prognostic Biomarker in Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma
por: Ding, Lin, et al.
Publicado: (2022)

Corrigendum to “EF24 Suppresses Invasion and Migration of Hepatocellular Carcinoma Cells In Vitro via Inhibiting the Phosphorylation of Src”
por: Zhao, Ran, et al.
Publicado: (2021)

Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

Corrigendum to Long Noncoding RNA PTTG3P Expression Is an Unfavorable Prognostic Marker for Patients With Hepatocellular Carcinoma
Publicado: (2020)

Corrigendum to Hypoxia‐induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway
Publicado: (2022)

Corrigendum to “Lycium Berry Polysaccharides Strengthen Gut Microenvironment and Modulate Gut Microbiota of the Mice”
por: Xia, Wenrui, et al.
Publicado: (2020)

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis [Corrigendum]
Publicado: (2020)

Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients
por: Chen, Lujun, et al.
Publicado: (2019)

Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo [Corrigendum]
Publicado: (2020)

GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma [Corrigendum]
Publicado: (2022)

Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”
por: Qian, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_54qevobmr6udiragjiqf00enkr